13 results about "CD155" patented technology

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and / or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and / or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and / or TIGIT.

The present invention relates to the technical field of immune engineering, and in particular to a CD155-targeting antibody or antigen-binding fragment and a use thereof. The antibody comprises a heavy chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 23 and a light chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 24, or a heavy chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 25 and a light chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 26. The antibody has an excellent binding capability with CD155, and CAR-T cells constructed on the basis of the antibody have a significant killing capability against tumor cells expressing CD155, as well as an obvious cellular internalization effect, the capability of promoting the cytotoxic effect of NK cells, and the capability of promoting the phagocytosis effect of macrophages, thereby exhibiting an excellent anti-tumor effect.

The application provides an immune cell preparation method capable of reversing tumor microenvironment immunosuppression signals and application thereof. The method for reversing the inhibitory signals is to replace the intracellular segment of a TIGIT receptor with a 4-1BB costimulatory domain and an IL-18R and a CD3 intracellular segment, and the immune cells expressing the chimeric antigen receptor recognize CD155 in a tumor microenvironment through TIGIT, avoid loss of function or exhaustion of the immune cells, and stimulate the immune cells to exert stronger tumor killing activity.

The present invention provides anti-CD155 antibodies and their applications, and provides anti-CD155 chimeric antibodies, humanized antibodies, and affinity-matured humanized antibodies, which specifically target and bind to the CD155 receptor, inhibit the binding of CD155 to its receptors TIGIT, CD96, and CD226, and have the characteristic of not inducing apoptosis of CD155 cells.

The present invention aims to solve the problem of providing a novel combination therapy with excellent antitumor effects. The present invention provides an antitumor agent (excluding pembrolizumab as an active ingredient) which includes as an active ingredient, fobamintib or a pharmaceutically acceptable salt thereof, to be administered in combination with an immune checkpoint inhibitor (excluding a CD155 / TIGIT pathway antagonist) and at least one or more other antitumor agents to a cancer patient.

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

The application provides a bispecific antibody and application thereof, and the antibody is a double-chain antibody, which comprises a first peptide chain and a second peptide chain, wherein the first peptide chain comprises a CD3 single-chain antibody and a first Fc region, and the CD3 single-chain antibody comprises a heavy chain variable region and a light chain variable region; the second peptide chain comprises a TIGIT extracellular region and a second Fc region; the C terminal of the CD3 single-chain antibody is connected with the N terminal of the first Fc region; and the C terminal of the TIGIT extracellular region is connected with the N terminal of the second Fc region. The prepared bispecific antibody can simultaneously target CD3 and CD155, thereby mediating the killing of tumor cells by T cells, and has strong tumor inhibition capacity.

The present application provides a polypeptide, a novel multi-target chimeric antigen receptor and application thereof. The polypeptide comprises a TIGIT extracellular region polypeptide and a PD1 extracellular region polypeptide, wherein the TIGIT extracellular region polypeptide has one or more mutations compared with a TIGIT reference sequence; the PD1 extracellular region polypeptide has one or more mutations compared with a PD1 reference sequence; the TIGIT reference sequence is an amino acid sequence as shown in SEQ ID NO: 9; and the PD1 reference sequence is an amino acid sequence as shown in SEQ ID NO: 13. Thus, the polypeptide of the present application has excellent affinity to CD155, and also exhibits excellent affinity to PD-L1, and can realize the synergistic recognition of multi-targets such as PD-L1 and CD155.

The present application provides: an anti-CD155 antibody or an antigen-binding fragment thereof; a conjugate of the antibody or antigen-binding fragment thereof and a drug; a composition for detecting CD155, a composition for diagnosing cancer, and a pharmaceutical composition for preventing, ameliorating, or treating cancer, each comprising the antibody or antigen-binding fragment thereof; and a pharmaceutical composition for preventing, ameliorating, or treating cancer comprising the conjugate, and thus achieves a better anticancer effect.

To provide a novel combination therapy that exhibits excellent antitumor effects. [Solution] An antitumor agent containing futivatinib or a salt thereof as the active ingredient (not containing pembrolizumab as the active ingredient) administered in combination to cancer patients with an immune checkpoint inhibitor (excluding CD155 / TIGIT pathway antagonists) and at least one other antitumor agent.

The present application provides an anti-CD155 antibody or an antigen-binding fragment thereof; a composition for detecting CD155, a composition for diagnosing cancer, and a pharmaceutical composition for preventing, ameliorating, or treating cancer, each comprising the antibody or antigen-binding fragment thereof; and a conjugate of the antibody or antigen-binding fragment thereof and a drug, and uses thereof for treating cancer, thereby achieving superior anticancer effects.

The invention provides a bispecific antibody targeting PVRIG and TIGIT and an application of the bispecific antibody. The bispecific antibody comprises a first antigen binding region and a second antigen binding region, wherein the first antigen binding region has PVRIG molecular binding activity; and a second antigen binding region, wherein the second antigen binding region has TIGIT molecule binding activity; wherein the first antigen binding region is connected with the second antigen binding region. The bispecific antibody prepared by the invention can be combined with human PVRIG and TIGIT proteins with high affinity, and can effectively block the combination of PVRIG and CD112 and the combination of TIGIT and CD155, thereby promoting the killing of human PBMC on tumor cells and enhancing the cytokine secretion function of CD8T cells.